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ABSTRACT 31 
Pituitary adenomas cause significant endocrine and mass-related morbidity. Only little is known 32 
about mechanisms underlying pituitary tumor pathogenesis. We searched for a side population (SP) 33 
in pituitary tumor, representing cells with high efflux capacity and potentially enriching for tumor 34 
stem cells (TSC). Human pituitary adenomas contain a SP irrespective of hormonal phenotype. This 35 
adenoma SP, as well as the purified SP (pSP) depleted from endothelial and immune cells, enriches 36 
for cells that express ‘tumor stemness’ markers and signaling pathways, including epithelial-37 
mesenchymal transition (EMT)-linked factors. Pituitary adenomas were found to contain self-38 
renewing sphere-forming cells, considered a property of TSC. These sphere-initiating cells were 39 
recovered in the pSP. Because benign pituitary adenomas do not grow in vitro and failed to expand in 40 
immunodeficient mice, the pituitary tumor cell line AtT20 was further used. We identified a SP in this 41 
cell line and found it more tumorigenic than the non-SP ‘main population’. Of the two EMT-42 
regulatory pathways tested, inhibition of C-X-C chemokine receptor type 4 (Cxcr4) signaling reduced 43 
EMT-associated cell motility in vitro as well as xenograft tumor growth, whereas activation of TGFβ 44 
had no effect. The adenoma pSP also showed upregulated expression of the pituitary stem cell 45 
marker SOX2. Pituitaries from dopamine receptor D2 knockout (Drd2-/-) mice bearing prolactinomas, 46 
contain more pSP, Sox2
+
 and colony-forming cells than wildtype glands. In conclusion, we detected a 47 
SP in pituitary tumor and identified TSC-associated characteristics. Our study adds new elements to 48 
the unravelment of pituitary tumor pathogenesis and may lead to new therapeutic targets. 49 
50 
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INTRODUCTION 51 
Pituitary tumors are generally considered as benign adenomas. Radiology and autopsy, often 52 
performed for other-than-pituitary-related medical reasons, show a high prevalence of 10-15% in the 53 
overall population although most of these lesions are small and asymptomatic (Daly et al. 2009; 54 
Melmed 2011). Clinically relevant pituitary adenomas have a lower prevalence of ∼0.1% (Daly et al. 55 
2009), but still represent the third most frequent intracranial neoplasm after meningiomas and 56 
gliomas. Tumorigenesis in the pituitary can pose serious medical complications. Tumors may 57 
hypersecrete one or more of the pituitary hormones, leading to severe endocrine disturbances and 58 
pernicious impact on the many physiological processes governed by the gland. Growth hormone 59 
(GH)-producing adenomas (somatotropinomas, GH-A) cause gigantism or acromegaly, ACTH-60 
producing tumors (corticotropinomas, ACTH-A) lead to Cushing’s disease and prolactin (PRL)-61 
producing adenomas (prolactinomas, PRL-A) negatively affect gonadal status and reproduction. 62 
Conversely, a large number of pituitary tumors do not measurably secrete hormones (i.e. non-63 
functioning adenomas, NF-A), but their growth and expansion may lead to deficient function of the 64 
gland (hypopituitarism) and visual disturbances due to compression of the optic chiasm and nerves. 65 
In general, 30-45% of the clinically diagnosed adenomas display this local expansion as well as 66 
invasion of neighboring structures such as the bony sphenoid sinus and the parasellar venous 67 
cavernous sinuses (Galland et al. 2010). Current therapeutic approaches that include transsphenoidal 68 
resection, pharmacotherapy and irradiation remain inadequate in a significant number of patients 69 
(Daly et al. 2009; Galland et al. 2010). The degree of invasiveness appears a critical determinant for 70 
the success rate of surgical removal and thus for relapse. At present, mechanisms underlying the 71 
pathogenic processes of initiation, expansion, invasion and/or relapse of pituitary tumors are largely 72 
uncomprehended. Only a minority (∼5%) of the tumors are hereditary and traced back to genetic 73 
mutations, existing either as isolated tumors or as a component of a larger endocrine syndrome like 74 
Men-1 (Daly et al. 2009; Melmed 2011). 75 
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In other types of tumors, so-called cancer stem cells (CSC) have been identified, a pool of 76 
relatively undifferentiated transformed cells that self-renew and propagate the entire range of tumor 77 
cell progeny. Compared to the other cells in the tumor, the CSC subpopulation is considered more 78 
tumorigenic and more resistant to therapy, thereby surviving treatment and finally re-growing the 79 
(heterogeneous) tumor (Vankelecom & Gremeaux 2010; Clevers 2011; Vankelecom 2012; 80 
Vankelecom & Chen 2014). Recently, CSC have been reported to display characteristics of epithelial-81 
mesenchymal transition (EMT) which may drive these cells in tumor expansion and invasive activity 82 
(Mani et al. 2008; Morel et al. 2008; Kong et al. 2010; Pirozzi et al. 2011; Yoon et al. 2012). EMT 83 
represents a multi-step cell-conversion process during which epithelial cells gradually acquire 84 
mesenchymal features. Cells change morphology, lose polarity and cell-cell contacts (e.g. by loss of E-85 
cadherin), become mobile with enhanced invasive capacity, and acquire increased resistance to 86 
apoptosis. More in general, EMT is known to play a key role in cancer pathogenesis, particularly 87 
during growth, maintenance (including resistance to hostile conditions) and progression of the tumor 88 
with local invasion and/or metastasis (De Craene & Berx 2013). In several types of cancer, it was 89 
discovered that EMT markers are enriched in the CSC fraction, that induction of EMT causes 90 
upregulated expression of ‘stemness’ genes, and that EMT acts as a key driver in the generation and 91 
activity of the CSC (Mani et al. 2008; Morel et al. 2008; Kong et al. 2010; Pirozzi et al. 2011; Yoon et 92 
al. 2012). 93 
Although presence and functional (or clinical) relevance of CSC is increasingly documented in a 94 
variety of cancers (Clevers 2011; Eppert et al. 2011; Chen et al. 2012; Schepers et al. 2012; Boumahdi 95 
et al. 2014; Vanner et al. 2014; Zhu et al. 2014), the concept remains debated and is likely not 96 
applicable to all types of cancer. Nonetheless, the model may help to understand pathogenesis, 97 
therapy resistance and recurrence of tumors. At present, CSC have mostly been identified in 98 
malignant types of cancer. Whether benign tumors also contain CSC (then better referred to as 99 
tumor stem cells or TSC) has only limitedly been studied (Vankelecom & Gremeaux 2010; Lapouge et 100 
al. 2011; Boumahdi et al. 2014). The search for CSC is generally performed on the basis of ‘stemness’-101 
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associated membrane markers or of functional traits. High efflux capacity, mediated by ATP-binding 102 
cassette (ABC) multidrug transporters, is considered one functional property of CSC, rendering the 103 
cells more resistant to chemotherapeutic drugs. In the present study, we searched for cells 104 
possessing such efflux capacity using the ‘side population’ (SP) technique (Chen et al. 2005, 2009). 105 
Cells extruding Hoechst dye are observed as a side branch of Hoechst
low
 cells in dual-wavelength 106 
FACS analysis. In a variety of cancer types, a SP has been identified and found enriched in CSC or CSC-107 
like cells (Patrawala et al. 2005; Wu & Alman 2008; Kato et al. 2010; Britton et al. 2012; Moti et al. 108 
2014). Thus, we searched for SP cells in human pituitary adenomas and in additional models of 109 
pituitary tumor (mouse tumor, cell line, xenograft tumors). We identified a SP and observed 110 
molecular and functional characteristics supportive of a TSC-associated phenotype. In addition, we 111 
identified the Cxcr4 pathway as an interesting target for further investigation in pituitary tumor 112 
treatment. 113 
114 
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MATERIALS AND METHODS 115 
Pituitary adenomas 116 
Human pituitary adenoma samples were obtained immediately after transsphenoidal resection 117 
at the University Hospitals Leuven (Division Neurosurgery). Informed consent was received from the 118 
patients. Hormonal phenotype was determined by the Department of Imaging and Pathology 119 
(University Hospitals Leuven). An overview of the samples with clinical data is provided in Table 1. 120 
Genders are represented equally with an average age of 53 yr (range: 19-84 yr) at the time of surgery. 121 
The majority of the tumors are NF-A (n=34) and GH-A (n=21). Other types of resected pituitary 122 
tumors typically are microadenomas only yielding sufficient study material in a limited number of 123 
cases (ACTH-A; n=3), or are not surgically removed but treated pharmacologically (resected PRL-A; 124 
n=2). 125 
Tumor samples were either immediately processed for flow-cytometric analysis after resection, 126 
or cryopreserved as small pieces in Leibovitz-L-15 medium (Life Technologies, Carlsbad, CA) 127 
supplemented with 10% fetal bovine serum (FBS; Lonza, Rockland, ME) and 10% dimethylsulfoxide 128 
(DMSO; Sigma-Aldrich, Bornem, Belgium) followed by storage at -196°C for later examination. The 129 
freezing procedure did not change the SP proportion (see Supplementary Fig. S1) or the expression 130 
characteristics as evident from the microarray analyses. 131 
 132 
Dissociation of human pituitary adenoma into single cells 133 
Tumor samples were rinsed in Dulbecco’s Modified Eagle’s Medium (DMEM; Life Technologies) 134 
supplemented with 0.3% bovine serum albumin (BSA; Serva, Heidelberg, Germany) and incubated 135 
with collagenase type IV (1mg/ml in Medium 199; Life Technologies) for 2-2.5 hr at 37°C. Cell debris 136 
was removed by centrifugation through a 3% BSA layer. The resultant cell pellet was resuspended in 137 
pituitary-optimized, serum-free chemically defined medium (SFDM, Life Technologies; supplemented 138 
with 0.5% BSA; Chen et al. 2005, 2009) for further analyses. 139 
 140 
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Immunohistology of human pituitary adenoma sections 141 
Formalin-fixed paraffin-embedded pituitary adenoma blocks were obtained from the Biobank 142 
(University Hospitals Leuven). Antigen retrieval was performed on 5-µm sections using EnVision FLEX 143 
Target Retrieval Solution (Dako, Glostrup, Denmark). Endogenous peroxidase activity was blocked 144 
using EnVision Peroxidase-Blocking Reagent and sections were incubated with primary antibodies 145 
directed against human E-cadherin (Ready-to-use; Dako), vimentin (1/500; Dako), NOTCH2 (1/200; 146 
Abcam, Cambridge, UK) and IL-6 (1/200; Abcam). Subsequently, samples were processed using 147 
EnVision Dual Link (Dako). The complex formed was visualized with 3,3'-diaminobenzidine (DAB; 148 
Dako) and sections were counterstained with hematoxylin (Dako). 149 
 150 
Isolation and dissociation of mouse pituitary 151 
C57/Bl6 mice were purchased from Elevage Janvier (BioServices, Uden, The Netherlands), and 152 
dopamine D2 receptor knockout (Drd2-/-) mice from The Jackson Laboratory (Bar Harbor, ME). Mice 153 
were kept or bred in the KU Leuven Animal Facility under conditions of constant temperature, 154 
humidity and day-night cycle in a sterile environment. Food and water were supplied ad libitum. 155 
Animal experiments were approved by the KU Leuven Ethical Committee. 156 
The pituitary was isolated from euthanized mice as previously described (Chen et al. 2005, 157 
2009). The anterior lobe (anterior pituitary, AP) of the Drd2
-/-
 mice growing prolactinomas (from 6 to 158 
14 months of age; Cristina et al. 2006), and of the respective control mice (Drd2
+/-
 and Drd2
+/+
) was 159 
dispersed into single cells using collagenase type IV as explained above for human pituitary 160 
adenomas. 161 
 162 
Culture and treatment of AtT20 163 
The mouse corticotrope AtT20 cell line was obtained from American Type Culture Collection 164 
(ATCC, CCL-89; Manassas, VA). The cell line was authenticated by hormone expression analysis with 165 
RT-quantitative (q)PCR (see below). The cells were cultured in DMEM/F12 (Life Technologies) 166 
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supplemented with 10% FBS. To investigate involvement of the transforming growth factor-β (TGFβ) 167 
or Cxcr4 pathways, AtT20 cells were cultured in serum-free medium for 18-24 hr and then treated 168 
with TGFβ1 (5ng/ml; R&D Systems, Minneapolis, MN) or AMD3100 (octahydrochloride, 100ng/ml; 169 
Sigma-Aldrich), respectively. Medium was refreshed every 24 hr. To analyze gene expression and SP 170 
proportion after treatment (see below), cells were detached and dissociated using trypsin (0.05%) 171 
with EDTA (0.02%; Life Technologies). 172 
 173 
Flow cytometry 174 
Dissociated cells (from human adenoma or mouse AP, AtT20 cell line or xenograft tumors – see 175 
below) were processed for SP analysis as described in detail before (Chen et al. 2005, 2009). In short, 176 
cells were incubated with the vital dye Hoechst33342 (Sigma-Aldrich) at a final concentration of 177 
2.5µg/ml (for mouse AP and AtT20) or 5µg/ml (for adenoma and xenograft samples). Subsequently, 178 
cells were either immediately analyzed by FACS (Vantage or Aria III; BD Biosciences) or first stained 179 
with phycoerythrin (PE)-conjugated mouse anti-human CD45, FITC-conjugated mouse anti-human 180 
CD31, PE-conjugated mouse anti-mouse CD45 and/or FITC-conjugated rat anti-mouse CD31 181 
antibodies, using dilutions recommended by the manufacturer (BD Biosciences). Samples were 182 
examined for SP on the basis of dual-wavelength emission using appropriate filters (Vantage: 424/44 183 
and 630/22; Aria III: 450/40 and 630/20) after (near-)UV excitation (360 and 375nm on Vantage and 184 
Aria III, respectively). The SP phenotype was verified by adding verapamil (100µM; Sigma-Aldrich) 185 
which blocks the Hoechst efflux. The bulk cell population not expelling Hoechst is designated as the 186 
‘main population’ (MP). CD31 and CD45 staining was controlled using isotype antibodies (BD 187 
Biosciences; data not shown).  188 
 189 
Xenograft tumors and in vivo tumorigenic activity 190 
In an attempt to grow human pituitary adenoma in immunodeficient mice, tumor pieces or 191 
dissociated cells (1-1.5x106) were transplanted subcutaneously (sc) (GH-A and NF-A, n=8) or under 192 
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the kidney capsule (GH-A and ACTH-A, n=3). Male mice (6-10 weeks old) with increasing grade of 193 
immunodeficiency (from SCID, NOD-SCID to NOD-SCID
IL2Rγ-/-
) were purchased from Elevage Janvier, 194 
and were anesthetized with Avertin (tribromoethanol; Sigma-Aldrich). Prior to injection, cells were 195 
resuspended in DMEM mixed with Matrigel (1:1; BD Biosciences). Three to six months later, mice 196 
were examined for tumor growth after euthanasia. Tissue of implantation sites was dissected and 197 
hematoxylin/eosin (H&E) staining performed. 198 
To grow xenograft tumors from AtT20 cells, SCID mice (male; 6-10 weeks old) were sc injected 199 
with 5x105 cells. To assess tumorigenic (TSC) activity of the AtT20 SP versus the MP, cell populations 200 
were sorted into DMEM/F12/10% FBS, mixed with Matrigel (1:1), and sc injected at different cell 201 
numbers into SCID mice (SP cells in one flank, the similar number of MP cells in the other flank of the 202 
same mouse). Tumor size was measured using a caliper and volume calculated with the formula 203 
‘[(large side) x (small side)²] x 0.52’. 204 
To explore the involvement of the Cxcr4 pathway, AtT20 xenograft tumors developing in SCID 205 
mice were treated with AMD3100 by intratumoral injection (5μg, two times/week), starting from day 206 
21 after sc AtT20 cell implantation. 207 
 208 
Tumorsphere- and colony-forming assay 209 
Dissociated human pituitary adenoma cells were seeded at a density of 100 000 cells/ml in 35-210 
mm non-treated culture dishes (Iwaki, Scitech, Chiba, Japan) and cultured in SFDM, supplemented 211 
with B27 (1:50; Life Technologies) and recombinant basic fibroblast growth factor (bFGF, 20ng/ml; 212 
R&D Systems). Fresh medium was added every 3 days. To assess self-renewal capacity, spheres were 213 
harvested, dissociated into single cells using trypsin (Chen et al. 2009) and cells re-seeded under 214 
similar conditions. 215 
To evaluate colony-forming capacity, cells were cultured at low density (1000-4000 cells/60-mm 216 
dish) in Ultraculture medium (Life Technologies) to which 5% FBS, 20ng/ml bFGF and 50ng/ml 217 
cholera toxin (Sigma-Aldrich) were added. Medium was changed every 3 days. Cultures were fixed 218 
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with methanol and stained with 1,9-dimethyl-methylene blue (Sigma-Aldrich), and the number of 219 
colonies was determined. Live pictures of the formed spheres and colonies were taken using a Nikon 220 
Eclipse TS100 microscope (Nikon Instruments, Melville, NY). 221 
 222 
Cell motility assay 223 
Cell motility was evaluated using the ‘scratch assay’. After reaching 90% of confluence, AtT20 224 
cells were serum-starved for 24 hr and then treated with mitomycin C (10μg/ml; Kyowa, Tokyo, 225 
Japan) to inhibit cell proliferation. A straight scratch was created and cells were further kept in 226 
DMEM/F12, together with TGFβ1 (5ng/ml), AMD3100 (100ng/ml) or vehicle. Medium was changed 227 
every 24 hr. Migration of cells into the scratch was evaluated by light microscopy and live pictures 228 
were taken with the Nikon Eclipse TS100 microscope at different time points. The open area was 229 
calculated using analysis algorithm-based T-scratch software (CSElab–ETH, Zürich, Switzerland). 230 
 231 
Small-animal magnetic resonance imaging 232 
Magnetic resonance imaging (MRI) was performed on Drd2-/- and Drd2+/- mice using a horizontal 233 
9.4-Tesla nuclear magnetic resonance spectrometer and a 40-mm-diameter birdcage coil as radio 234 
frequency transmitter and receiver. Mice were anesthetized using 1% isoflurane in a mixture of 75% 235 
air and 25% oxygen. T1-weighted images were acquired using a two-dimensional multiple-slice spin 236 
echo sequence, with an echo time of 11 msec, a repetition time of 500 msec, in-plane resolution of 237 
0.1x0.1 mm, 24 coronal slices with 0.3-mm slice thickness, and 10 signal averages. Image 238 
reconstruction was performed using the spectrometer console. Ten minutes prior to the scanning 239 
procedure, mice received an intraperitoneal injection of the contrast agent gadolinium (0.50mmol/kg 240 
body weight). 241 
242 
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Immunofluorescence analysis 243 
For immunofluorescence examination of mouse pituitaries, whole glands were isolated and 244 
fixed with paraformaldehyde (4%; Riedel-de Haën, Seelze, Germany). After agarose embedding, 245 
pituitaries were coronally sectioned to 45-μm slices using a vibratome (Microm HM 650V; Prosan, 246 
Merelbeke, Belgium). Sections were permeabilized with 0.4% Triton-X 100 (Sigma-Aldrich) and 247 
incubated overnight with the following primary antibodies: goat anti-human SOX2 (1/750; Immune 248 
Systems, Devon, UK) and rabbit anti-mouse prolactin (PRL) (1/10 000; from Dr. A.F Parlow, NHPP, 249 
Harbor-UCLA Medical Center, Torrance, CA). Finally, sections were incubated with AlexaFluor 488-250 
conjugated donkey anti-rabbit and/or AlexaFluor 555-conjugated donkey anti-goat antibodies 251 
(1/1000; Life Technologies), and nuclei labeled with ToPro3 (Life Technologies). Immunofluorescence 252 
was examined using a Zeiss LSM 510 confocal laser-scanning microscope (Zeiss, Zaventem, Belgium) 253 
accessible through the Cell Imaging Core (CIC; KU Leuven). Z-stacks were collected and analyzed 254 
using Zeiss LSM Image Browser and ImageJ (http://imagej.nih.gov/ij/), and pictures were prepared 255 
using the same programs and Microsoft PowerPoint (2007). 256 
Immunofluorescence staining of paraffin-embedded mouse pituitary sections (5μm) was 257 
performed after antigen retrieval with citrate buffer (pH 6) and permeabilization with Triton-X 100 258 
(0.1% in PBS). Following incubation with primary and secondary antibodies (as above), sections were 259 
covered with Vectashield (containing 4’,6-diamidino-2-phenylindole or DAPI) and analyzed using a 260 
Leica DM5500 epifluorescence microscope (Leica Microsystems, Diegem, Belgium) accessible 261 
through InfraMouse (KU Leuven-VIB). Recorded images were converted to pictures with ImageJ and 262 
Microsoft PowerPoint (2007). 263 
Cytospin samples of dissociated mouse AP cells were fixed with paraformaldehyde (4%), 264 
permeabilized with saponin (0.5%; Sigma-Aldrich), and further immunostained for Sox2 (with goat 265 
anti-human SOX2 at 1/250; Immune Systems) as described above. In some analyses, cells were at the 266 
same time immunostained for the proliferation marker Ki67 (with rabbit anti-Ki67 at 1/50; Thermo 267 
Scientific, Fremonet, CA). Nuclei were counterstained with DAPI (0.5μg/ml). To enumerate Sox2-268 
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immunopositive cells, pictures were captured using the Leica DM5500 microscope, and cells counted 269 
with ImageJ in 5 to 10 random fields per group in each experiment (about 1500 cells per group in 270 
each experiment). The proportions of the Sox2
+
 cells (on total cells counted) were determined. 271 
Because of the increase of total AP cells in the Drd2-/- adenomatous pituitary, comparison of 272 
proportions is not appropriate. Thus, absolute numbers of Sox2
+
 cells were calculated (using their 273 
proportion and the total number of AP cells obtained per experimental group of mice) for 274 
comparison between Drd2
-/-
, Drd2
+/-
 and Drd2
+/+
 mice. 275 
For immunofluorescence examination of tumorspheres developed from human pituitary 276 
adenomas, fixation with paraformaldehyde (4%) and permeabilisation with Triton-X100 (0.4% in PBS) 277 
were followed by incubation with goat anti-human SOX2 (1/250; Immune Systems), rat anti-mouse 278 
nestin (1/500; Abcam) and/or rabbit anti-human GH (for spheres originating from GH-A; 1/2000; 279 
Dako). Secondary antibodies included AlexaFluor 555-conjugated donkey anti-goat, AlexaFluor 488-280 
conjugated donkey anti-rat, and AlexaFluor 488-conjugated donkey anti-rabbit (all at 1/1000; Life 281 
Technologies). Pictures were obtained with the Leica DM5500 epifluorescence microscope as 282 
described above. 283 
 284 
AtT20 cell death, apoptosis and proliferation 285 
The number of dying or dead AtT20 cells after AMD3100 treatment (100ng/ml) was determined 286 
after staining with Trypan Blue (0.4%; Sigma-Aldrich). Apoptosis was scored by TUNEL (Terminal 287 
deoxynucleotidyl transferase dUTP nick end labeling) analysis in cytospin samples of AtT20 cells from 288 
culture or xenograft tumors, using the FragEL kit (Calbiochem, Darmstadt, Germany). Cell 289 
proliferation was quantified by immunofluorescence staining of cytospin samples for Ki67 as 290 
described above. Pictures were taken and cells enumerated (see above). 291 
 292 
293 
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Whole-genome expression profiling 294 
Total SP and MP cells (NF-A, n=5; GH-A, n=4) or CD31¯/CD45¯ SP (purified SP or pSP) and pMP 295 
cells (NF-A, n=5) were sorted by FACS into cold lysis solution of the RNeasy Micro Kit (Qiagen, Venlo, 296 
The Netherlands). Total RNA was extracted immediately after cell collection according to the 297 
manufacturer’s guidelines. RNA samples were stored at -80°C until further processing for whole-298 
genome expression profiling (in collaboration with the VIB Nucleomics Core, KU Leuven). RNA quality 299 
and concentration were determined using Agilent Picochips on an Agilent BioAnalyzer 2100 (Agilent 300 
Technologies, Santa Clara, CA). Two ng of high-quality RNA (with RNA Integrity Number ≥8.0) was 301 
amplified using the NuGen Pico WTA kit (NuGen Technologies, San Carlos, CA). Cy3 label was 302 
incorporated into the cRNA probes which were then hybridized onto Agilent whole human genome 303 
44K oligonucleotide arrays. Slides were scanned and data processed using the Agilent’s Feature 304 
Extraction Software for background correction, quantile normalization, Principal Component Analysis 305 
(PCA), hierarchical clustering, and MA and Volcano plots. Microarray data are available from the 306 
NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/geo/) through series 307 
accession number GSE62960. 308 
To determine differentially expressed genes (probes), a stringent analysis was initially applied to 309 
the normalized data sets. Taken into account that the data are paired (SP versus MP for each 310 
sample), analysis was based on the log2-ratios computed for each pair. Log2-ratios were compared 311 
with the Limma (Linear Models for Microarray Data) package of Bioconductor in R and a moderated 312 
t-statistic (implemented in Limma) was performed to test the significance of the obtained 313 
differences. For the first microarray data set (total SP versus MP), the resulting p-values were 314 
corrected for multiple testing with Benjamini-Hochberg to control the false discovery rate. 315 
Differentially expressed genes were withheld when the corrected p-value was lower than 0.05. For 316 
the second microarray data set (CD31¯/CD45¯ SP versus CD31¯/CD45¯ MP), Benjamin-Hochberg 317 
could not be applied because of the low number of samples. Therefore, a cut-off based on the 318 
uncorrected p-values (p<0.001) was utilized. For both data sets, the cut-off on the p-values was 319 
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combined with a cut-off on the fold change (≥2) to finally determine the differentially expressed 320 
genes. 321 
Given the not yet large number of adenomas analyzed, causing a very high cut-off for 322 
differential expression and hence the discard of potentially interesting differences, we additionally 323 
applied a less stringent analysis by paired Students t-test performed on the individual probe sets. 324 
Genes were judged differentially expressed when p<0.05 and fold change ≥1.5. We further 325 
considered genes that showed a significant expression difference in not all but in 5 to 8 out of the 9 326 
adenomas analyzed for total SP and MP, and in 2 to 4 out of the 5 adenomas examined for 327 
CD31¯/CD45¯ fractions. 328 
Functional clustering analysis of differentially expressed genes (Gene Ontology, GO) was 329 
performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, 330 
version 6.7; www.david.abcc.ncifcrf.gov). Gene clusters with enrichment score >1.5 (-log of the 331 
median p-value for the functional group) were retained. Finally, we narrowed the gene sets by 332 
focusing on factors shown to be important in CSC/‘tumor stemness’ including EMT, NOTCH, WNT/β-333 
CATENIN and TGFβ/BMP. 334 
 335 
Gene expression analysis by RT-qPCR 336 
Amplified cDNA of the CD31¯/CD45¯ SP and MP fractions from the 5 microarrayed NF-A samples, 337 
as well as from 2 additional samples (NF-A, n=1; GH-A, n=1; see Table 1), was examined by RT-qPCR 338 
to validate expression of a selection of genes using Fast SYBR Green Master Mix on an ABI 7900HT 339 
Fast RT-PCR system, performed according to the manufacturer’s instructions (Life Technologies). 340 
Gene expression analysis of AtT20 cells or dispersed xenograft tumors occurred using a similar 341 
approach (but without the RNA amplification step). cDNA was subjected to qPCR in a LightCycler 480 342 
using the LightCycler FastStart DNA Master Plus SYBR Green I (Roche, Basel, Switzerland). 343 
Forward and reverse primers were designed using PerLPrimer 344 
(http://perlprimer.sourceforge.net) or obtained from a public database 345 
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(http://medgen.ugent.be/rtprimerdb), and are described in Supplementary Table S1. 346 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β2-microglobulin (B2M) and/or hypoxanthine 347 
phosphoribosyltransferase 1 (HPRT1) were used to normalize gene expression. Their expression was 348 
found to be stable (data not shown). Relative gene expression levels were calculated as ∆Ct values 349 
(‘Ct target minus Ct reference’) and compared between the SP and MP as fold change  350 
(2-∆Ct SP/2-∆Ct MP). Statistical analysis was performed using Graphpad Prism (Version 5.2; Graphpad 351 
Software, La Jolla, CA) applying the Mann-Whitney U test. P-values <0.05 were considered as 352 
statistically significant. 353 
For authentication of the AtT20 cell line used, hormone gene expression was examined by RT-354 
qPCR. The corticotrope phenotype of the cell line was confirmed by detection of pro-355 
opiomelanocortin (POMC; precursor of ACTH) expression, while GH and thyroid-stimulating  356 
hormone-β (TSHβ) gene transcription was not found (see Supplementary Table S2). 357 
358 
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RESULTS 359 
Human pituitary tumors contain a side population 360 
Human pituitary adenomas (n=60; see Table 1) were examined for the presence of a SP. In all 361 
tumors analyzed, a Hoechstlow cell population was detected which was not observed anymore when 362 
the efflux-blocker verapamil was added together with Hoechst (Fig. 1A), thereby demonstrating the 363 
SP phenotype (mean SP ± SEM: 1.9% ± 0.3 of the total viable tumor cells; range: 0.4-17.2%; Table 1).  364 
SP proportions were not different between the samples analyzed immediately after surgical 365 
resection (n=24) or after cryopreservation (n=36) (Table 1; Supplementary Fig. S1A), neither between 366 
the different hormonal phenotypes examined (Fig. 1B; Table 1). The adenoma SP predominantly 367 
clusters cells of small to medium size (low ‘forward scatter’) and low granularity (low ‘side scatter’) 368 
(Supplementary Fig. S1B). 369 
 370 
Whole-genome expression profiling of the adenoma SP points to epithelial-mesenchymal 371 
transition and ‘tumor stemness’ 372 
SP cells and the tumor bulk MP cells from somatotropinomas (GH-A, n=4) and non-functioning 373 
adenomas (NF-A, n=5; see Table 1) were sorted by FACS and subjected to gene expression profiling 374 
using whole-genome microarrays. Principal component analysis (PCA) indicates a comparable 375 
segregation of the SPs from the corresponding MPs for the majority of the samples analyzed 376 
(Supplementary Fig. S1C). Hierarchical clustering of differentially expressed genes also largely 377 
separates the SPs from the MPs (Supplementary Fig. S1D). 378 
The set of genes most differentially expressed (p<0.001; 2760 probe sets) was submitted to 379 
DAVID for Gene Ontology (GO) analysis, yielding a total of 1688 corresponding human ENSEMBL IDs. 380 
Gene set enrichment exposes in the SP upregulation of biological functions involved in cell 381 
proliferation, vascular development, cell migration and motility, and lymphocyte activation 382 
(Supplementary Table S3). 383 
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A focused analysis of a selection of genes using the expression data of the 9 adenomas (Table 2 384 
and Supplementary Table S4) reveals upregulated expression (i.e. >1.5-fold in at least 2/3
rd
, or in 5 of 385 
the 9 tumors, p<0.05; see Materials and Methods) in the SP of the multidrug transporters ABCB1 and 386 
ABCG2 that typically underlie the SP phenotype, thereby validating the SP identification and sorting 387 
procedure. Remarkably, the transcriptome displays an expression pattern that supports occurrence 388 
of EMT in the SP compartment. The epithelial markers E-cadherin (CDH1) and claudin-1 (CLDN1) are 389 
downregulated in the pituitary adenoma SP whereas the mesenchymal markers vimentin (VIM) and 390 
fibronectin (FN1) are upregulated (Table 2 and Supplementary Table S4). Moreover, recognized 391 
markers of EMT such as SNAI1, ZEB1 and ZEB2 (all transcriptional repressors of the CDH1 gene) are 392 
higher expressed in the SP versus the MP together with other inductors and regulators of EMT (KLF8, 393 
LEF1, TCF4, FOXC1, HOXB9, FOSL2, MMP1/2 and CXCR4). Some of the pathways identified as 394 
upregulated are also well known for their regulatory input in EMT (WNT, TGFβ, epiregulin or ERG, 395 
amphiregulin or AREG). In this analysis, we also observed that factors often associated with ‘tumor 396 
stemness’ or CSC, including CD44, CXCR4, KIT, KLF4 and NESTIN are upregulated in the SP. In 397 
addition, the signaling pathways of NOTCH, WNT and TGFβ BMP have also been related to ‘tumor 398 
stemness’. Overall, no obvious differences were observed between the SP transcriptomes of the NF-399 
A and the GH-A samples. 400 
Of note, the microarray analysis also revealed upregulated expression of genes associated with 401 
an endothelial phenotype (such as PECAM1/CD31, VWF, CDH5, VCAM1, FLK1/KDR, TIE1, TEK/TIE2) or 402 
an immune character (such as CD45/PTPRC) in the adenoma SP (see Table 2 and Supplementary 403 
Table S4). These expression characteristics are in line with the enriched biological processes as 404 
described above (viz. vascular development and lymphocyte activation; see Supplementary Table S3) 405 
and suggest the presence of endothelial and immune/hematopoietic cells in the SP. Before, we and 406 
others have discovered that the SP, whether from healthy tissue or tumors, represents a still 407 
heterogeneous population, not only segregating cells with (tumor) stem cell properties but also some 408 
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other cells of endothelial and immune/hematopoietic phenotype (Chen et al. 2009; Pfister et al. 409 
2005; Uezumi et al. 2006). 410 
Taken together, our microarray expression data indicate that, compared with the MP, the 411 
pituitary adenoma SP is enriched in cells with EMT- and ‘tumor stemness’-associated molecular 412 
traits, but is still heterogeneous in cell phenotypes. 413 
 414 
EMT- and ‘tumor stemness’-related expression characteristics remain present in the adenoma SP 415 
depleted from endothelial and immune cells 416 
The pituitary adenoma SP was then analyzed for the presence of endothelial (CD31+) and 417 
immune/hematopoietic (CD45
+
) cells. Flow cytometry revealed a CD31
+
 cell population of varying 418 
abundance in the SP (mean ± SEM: 50.9 ± 4.8% of the SP; range: 5.8–95.2%; n=37; Fig. 1C-D and 419 
Table 1). Also CD45
+
 cells are found but in general constitute a lower fraction of the adenoma SP 420 
(16.2 ± 3.0% of the SP; range: 0.2-66.6%; n=31; Fig. 1C-D and Table 1). The non-endothelial, non-421 
immune (CD31¯/CD45¯) SP fraction finally comprises on average 1/3
rd
 of the total SP (32.3% ± 2.2; 422 
range: 7.2 – 64.1%), 0.5% (± 0.1) of all CD31¯/CD45¯ adenoma cells and 0.1% (± 0.01) of the total 423 
tumor cell population. In general, no correlation was found between the size of the total SP and the 424 
proportion of CD31
+
 or CD45
+
 cells (Table 1 and Fig. 1D), although the 2 samples with the highest SP 425 
proportion analyzed for these antigens (PA 26, PA 43) contain the largest fraction of CD31+ cells in 426 
the SP. 427 
To determine whole-genome expression profiles of the non-endothelial, non-immune cell 428 
populations, SP and MP were depleted from CD31
+
/CD45
+
 cells during flow-cytometric sorting (see 429 
Fig. 1C for gating; n=5 NF-A; Table 1). Stringent analysis revealed 101 genes (probe sets), 430 
corresponding to 74 human ENSEMBL IDs in DAVID, which are differentially expressed between the 431 
CD31¯/CD45¯ SP (further referred to as the purified SP or pSP) and the CD31¯/CD45¯ MP (pMP), 80 of 432 
which are upregulated in the pSP and 21 downregulated (see Supplementary Fig. S2A-C). The as yet 433 
relatively small number of samples analyzed causes a high cut-off for differential expression (as is 434 
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clear from Supplementary Fig. S2A). Therefore, we performed an additional, less stringent 435 
examination (see Materials and Methods), analyzing genes not only altered (≥ 1.5-fold, p<0.05) in all 436 
adenomas, but also in 4 out of the 5 tumors profiled. A total of 2374 genes (probe sets) were found 437 
to be differentially expressed in the pSP compared to the pMP in at least 4 of the adenoma samples 438 
(corresponding to 1576 human ENSEMBL IDs), with 1662 and 712 genes up- and downregulated, 439 
respectively (Supplementary Table S5). The gene sets obtained in both the stringent and less 440 
stringent analyses (101 and 2374 genes, respectively) were submitted to GO examination using 441 
DAVID. Overviews of the most significantly enriched biological processes are provided in 442 
Supplementary Table S6 and S7, and include, amongst others, cell motility and migration, vascular 443 
development, cell proliferation and organ development. 444 
Subsequent analysis of the pSP was focused on a selection of genes as considered above for the 445 
total SP, including genes associated with EMT and ‘tumor stemness’ (Table 3 and Supplementary 446 
Table S8). On the whole, the expression picture of the total SP appears retrieved in the CD31¯/CD45¯ 447 
SP, viz. upregulated expression of ABCG2 and of other CSC-associated markers including CD44, CD34, 448 
LIFR and CXCR4. KIT expression is upregulated in 4 of the 5 samples and NESTIN in 3 of the 5 (Table 3). 449 
In particular, the gene expression picture underlying EMT is also present in the pSP, showing 450 
elevated expression of the mesenchymal markers VIM and FN1 and of several transcriptional EMT 451 
regulators (including SNAI1, SNAI2, ZEB1, ZEB2) (Table 3). Since GO enrichment pointed to gene 452 
clusters involved in cell motility and migration, and EMT is known to drive motile and invasive 453 
behavior of cells, additional genes involved in these processes were examined. A considerable 454 
number were found to be up- or downregulated in the pSP versus the pMP including EPHB1 and 455 
TM4SF1 (Supplementary Table S8). Interestingly, also epidermal growth factor receptor (EGFR) is 456 
highly (9-fold) upregulated in the pSP (Supplementary Table S8); EGFR has been found to be involved 457 
in tumor cell migration in craniopharyngiomas (Hölsken et al. 2011). In addition, several components 458 
functioning in NOTCH, WNT and TGFβ signaling are elevated (Table 3 and Supplementary Table S8). 459 
These pathways play a role in EMT and ‘tumor stemness’ but also in pituitary development (Zhu et al. 460 
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2007; Vankelecom 2010). More in general, gene clusters associated with organ development and 461 
differentiation processes are found enriched in the pSP (see Supplementary Tables S4 and S5). Finally, 462 
also genes implicated in angiogenesis are upregulated in the pSP versus pMP (Table 3; 463 
Supplementary Tables S6, S7 and S8). 464 
Differential expression as concluded from the pSP microarray interrogations was verified by RT-465 
qPCR for a number of the most interesting genes (Fig. 1E). For this analysis, the 5 micro-arrayed NF-A 466 
samples were complemented with 2 additional tumors (1 NF-A and 1 GH-A; see Table 1). RT-qPCR 467 
was found to essentially confirm the microarray data, although statistical significance was not always 468 
reached in the as yet relatively limited number of samples analyzed. All 17 genes examined show 469 
upregulated expression in the pSP when compared to the pMP (9 with statistical significance, 8 with 470 
upward trend; Fig. 1E). Most remarkable are the elevated expression levels of CD44, IL-6, NOTCH2, 471 
PDGFRB, SNAI2, VIM and ZEB2, in the pSP over the pMP (>55-fold). A higher expression level (>55-472 
fold) was also found for CXCR4, FN1, HES1, PDGFC and TGFBR2, not in all but in at least 5 out of the 7 473 
samples. Expression of CDH1 was also checked but was not significantly different in the pSP versus 474 
the pMP, although a trend of downregulation was measured in the pSP of 4 out of the 7 adenomas 475 
analyzed. Expression of E-cadherin, vimentin, IL-6 and NOTCH2 was further analyzed by 476 
immunohistochemistry in paraffin-embedded sections of pituitary adenomas used above for gene 477 
expression analysis (n=6; see Table 1 and Supplementary Fig. S2D). Tumors with high E-cadherin 478 
immunoreactivity contain some zones and cell clusters where E-cadherin is downregulated, and 479 
vimentin is expressed in some regions or small nests of tumor cells (in addition to the pericapillar 480 
cells), suggesting that some tumor cells may have undergone EMT. IL-6 immunoreactivity was 481 
observed in a couple of clustered cells (2-4 per section) in 3 out of the 6 adenomas analyzed, and 482 
NOTCH2 immunoreactivity in 1-2 cells per section in 4 out of the 6 adenomas (Table 1 and 483 
Supplementary Fig. S2D). IL-6 and NOTCH2 immunoreactivity were found in the same adenomas, 484 
except for PA 34. 485 
486 
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Human pituitary tumors contain sphere-forming cells segregating to the pSP 487 
TSC generate spheres (‘tumorspheres’) when brought in appropriate suspension-culture 488 
conditions (Vankelecom & Gremeaux 2010; Clevers 2011). When pituitary adenoma cells were 489 
cultured in the presence of B27 and bFGF, free-floating spheres developed progressively. After 7 days 490 
of culture bright and mostly smooth-edged spheres were obtained which clearly differ from the 491 
irregular clumps of aggregated cells that also formed (Fig. 2A-B; n=13 encompassing NF-A and GH-A). 492 
Sphere cells were found to express the stemness markers Sox2 and nestin (Chen et al. 2009), thereby 493 
supporting their TSC character (Fig. 2C and Supplementary Fig. S3A-B; n=3: 1 NF-A and 2 GH-A). At 494 
the end of the culture period (day 7-10), some spheres contained cells expressing the hormone 495 
produced by the original tumor, suggesting some degree of spontaneous differentiation and further 496 
supporting their TSC phenotype (Supplementary Fig. S3C). To examine the self-renewal capacity of 497 
the sphere-initiating cells (as a further property of TSC), primary spheres were dissociated and cells 498 
seeded again. Secondary spheres with similar morphology developed although fewer in number (Fig. 499 
2D-E; n=9), likely due to a considerable loss of cells after dispersion of the primary spheres. Third-500 
generation spheres were further also obtained, but were still scarcer (Fig. 2F). 501 
To investigate whether the sphere-forming cells belong to the pituitary tumor’s SP, 502 
CD31¯/CD45¯ SP cells were sorted from adenomas and seeded in sphere-forming conditions (n=3). 503 
Spheres developed in the pSP cultures (Fig. 2G) and were absent from pMP cultures that only 504 
contained irregular clumps of cells (Fig. 2G, inset). However, only very few spheres could be obtained 505 
(2-4 spheres per 20 000 pSP cells originally seeded), which made it impossible to get enough viable 506 
cells for further passaging after dispersion. 507 
Together, our findings provide supportive evidence that human pituitary adenomas contain self-508 
renewing sphere-forming cells that give rise to spheres expressing stemness markers, considered as 509 
properties of TSC, and further show that the sphere-initiating cells segregate to the pSP. 510 
In addition to the in vitro sphere-forming assay, CSC/TSC activity is typically tested in vivo by 511 
(xeno-)transplantation in immunodeficient mice (Vankelecom & Gremeaux 2010; Clevers 2011; Chen 512 
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et al. 2012; Schepers et al. 2012; Boumahdi et al. 2014). However, we observed that human pituitary 513 
adenoma, irrespective of hormonal phenotype, does not grow (i.e. expand) in immunodeficient SCID 514 
mice. Although small tumor pieces survived for 3-4 months after sc implantation, no enlargement 515 
was detected (data not shown). Xenograft adenoma growth did not only fail in SCID mice but also in 516 
the more immunodeficient NOD-SCID and NOD/SCID
IL2Rγ-/-
 models, after sc implantation of tumor 517 
parts as well as of dissociated cells (data not shown). Similarly, pituitary adenoma fragments 518 
engrafted under the kidney capsule survived but did not visibly grow in size (as analyzed after 3-6 519 
months; Supplementary Fig. S4). Therefore, to be able to further functionally characterize the 520 
pituitary tumor SP and to explore its TSC-associated phenotype, we turned to a well-established 521 
pituitary tumor cell line, the mouse corticotrope AtT20, previously shown to grow tumors after sc 522 
implantation in immunodeficient mice (Taguchi et al. 2006). 523 
 524 
Characterization of AtT20’s SP and tumorigenic activity 525 
First, we examined whether the AtT20 cell line contains a SP. A verapamil-blockable Hoechst
low
 526 
cell population was detected, amounting to 1.0% ± 0.3 of total cells (n=12; Fig. 3A). This AtT20 SP 527 
shows upregulated expression of the analyzed ‘tumor stemness’ genes Cd44 and Cxcr4 (Fig. 3B). 528 
To study in vivo tumorigenic activity, we first verified the tumor-growing capacity of AtT20 cells 529 
in SCID mice. Sc injection of 5x105 cells results in a gradually developing tumor (Supplementary Fig. 530 
S5A), palpable after 15-20 days and further expanding in volume until the mouse becomes moribund, 531 
most likely due to corticoid overproduction because of enhanced adrenal stimulation by the AtT20-532 
produced ACTH (Taguchi et al. 2006). A SP remains present in the AtT20-derived xenograft tumors 533 
(as analyzed after 50-55 days), although the proportion is lower than in the cell line in culture (0.5% 534 
versus 1%; n=3). 535 
SP and MP cells were then sorted by FACS from cultured AtT20 cells, and varying numbers  536 
(10 000, 5000 and 1000 cells) sc injected into SCID mice. Although all cell populations induced tumor 537 
growth, SP-derived tumors expanded faster (Supplementary Fig. S5B) and/or became larger (Fig. 3C 538 
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and Supplementary Fig. S5B) when compared to MP-derived tumors. The SP cells developed a tumor 539 
with reconstitution of the SP/MP profile (0.5% SP; n=2) whereas the MP cells generated tumors with 540 
a lower SP portion (0.2%; n=2). Together, our results provide indications that the AtT20 SP has 541 
tumor-proliferative dominance, and that TSC(-like cells) are enriched, although not exclusively 542 
segregated, in the SP. 543 
 544 
Effects of EMT-regulatory pathways in the AtT20 cell line 545 
As described above, the transcriptomic data of the human pituitary adenomas support the 546 
presence of an EMT process in the (p)SP. Therefore, we tested the impact of two important EMT-547 
regulatory pathways (De Craene & Berx 2013), i.e. of TGFβ and Cxcr4, in the AtT20 cell line. 548 
Moreover, Cxcr4 has been identified as a marker of CSC(-like cells) in various types of cancer 549 
(Hermann et al. 2007; Vankelecom & Gremeaux 2010; Clevers 2011). As mentioned above, its 550 
expression is upregulated in the human pituitary adenoma pSP and the AtT20 SP (Table 3, Fig. 1E and 551 
Fig. 3B). Of note, these studies could not be performed with primary human pituitary adenoma cells 552 
since these cells cannot efficiently be kept in culture and do not grow (well) in vitro (Hofland & 553 
Lamberts 2002). 554 
Treatment of AtT20 cells with TGFβ1 for 72 hr significantly stimulated the expression of EMT 555 
factors Snai2 and Vim, while there was a clear upward trend for Snai1 and Cxcr4 (Fig. 4A). However, 556 
TGFβ1 treatment did not significantly enhance the motility of AtT20 cells, which is an expected 557 
functional consequence of EMT (Fig. 4B). Treatment of AtT20 cells in culture with TGFβ1 did not 558 
significantly increase the SP proportion (1.2% ± 0.1 versus 1.0% ± 0.3 in control culture; n=3; p>0.05). 559 
Along the same line, pretreatment of AtT20 cells with TGFβ1 did not lead to a higher tumor-growing 560 
capacity when sc transplanted in SCID mice, neither regarding onset, nor regarding progression 561 
(volume expansion) of the tumor (Supplementary Fig. S5C). 562 
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To analyze the involvement of the Cxcr4 pathway, we treated developing AtT20 xenograft 563 
tumors in SCID mice with the Cxcr4 antagonist AMD3100. Interestingly, tumors injected with 564 
AMD3100 grew at a slower rate and remained smaller than vehicle-injected tumors (Fig. 4C). 565 
We further observed that AMD3100 significantly reduced the migratory activity of AtT20 cells as 566 
analyzed in vitro (Fig. 4B), thus suggesting an impact on EMT. However, AMD3100 treatment did not 567 
significantly affect the expression level of the EMT-associated genes Zeb2, Snai1, Snai2 (although a 568 
downward trend was observed), Vim and Cdh1, and of the CSC-associated marker Cd44, as analyzed 569 
in the xenograft tumors after 20 days of treatment (Fig. 4D). In vitro, 72-hr AMD3100 treatment did 570 
also not affect expression levels of these genes, and had no significant effect (although tendancy) on 571 
the proportion of the SP (0.5% ± 0.3 versus 0.9% ± 0.2 in control; n=3; p>0.05). Of note, there was a 572 
small increase in Cxcr4 expression in the AMD3100-treated xenograft tumors (Fig. 4D); upregulation 573 
of Cxcr4 after AMD3100 treatment has also been reported in other tumors, supposedly due to 574 
adaptation of the tumor to sustained Cxcr4 signal inhibition (Domanska et al. 2012). Together, EMT 575 
genes – at least the ones analyzed - do not seem to be involved in the AMD3100-induced inhibition 576 
of cell motile activity and of xenograft tumor growth (at least as examined after 20 days of 577 
treatment). To search for possible other mechanisms of tumor growth reduction, cell viability and 578 
proliferation were evaluated. Treatment of cultured AtT20 cells with AMD3100 results in a 2- to 3-579 
fold increase in dying/dead cells (from 2-4% in control to 8-11% after AMD3100 treatment; Fig. 4E). 580 
In analogy, AMD3100 augments the number of AtT20 cells that go into apoptosis (about 2-fold; Fig. 581 
4F). However, no difference was found (anymore) in the number of apoptotic cells after 20-day 582 
AMD3100 treatment in vivo (data not shown). Treatment of cultured AtT20 cells with AMD3100 also 583 
reduces the proportion of proliferating cells (from about 90 to 60% after 72 hr; Fig. 4G). From these 584 
in vitro data, it is assumed that the tumor-growth inhibitory effect of AMD3100 at least partially 585 
involves a reduction in cell viability and proliferation. From our data so far, there are no indications 586 
yet that EMT is also implicated. 587 
 588 
Page 24 of 65
 25 
Pituitary tumorigenesis and pituitary stem cells 589 
In addition to the finding of SOX2 expression in tumorsphere cells, our microarray analysis also 590 
revealed upregulated gene expression of SOX2 in the adenoma pSP (>1.5-fold in 3 of the 5 human 591 
pituitary tumors analyzed; p<0.05). Interestingly, the AtT20 SP also shows higher expression of Sox2 592 
(as compared to the MP; Supplementary Fig. S6A). A comparable finding was observed in an 593 
additional pituitary tumor cell line, the rat lactosomatotrope GH3, also containing a SP (0.5% ± 0.05; 594 
n=18) (Supplementary Fig. S6A-B). Sox2 is a stemness factor which also marks the recently identified 595 
stem cells of the pituitary gland (Chen et al. 2009). In general, a link may exist between CSC/TSC of 596 
tumors in organs and the resident stem cells, as recently supported in several cancers (Barker et al. 597 
2009; Llaguno et al. 2009; Zhu et al. 2009; Mulholland et al. 2010; Vankelecom & Gremeaux 2010; 598 
Clevers 2011; Lapouge et al. 2011; Chen et al. 2012; Schepers et al. 2012; Boumahdi et al. 2014; 599 
Vankelecom & Chen 2014; Vanner et al. 2014). 600 
To further explore the pituitary stem cells in the gland’s tumors, we turned to the dopamine D2 601 
receptor knock out (Drd2
-/-
) mouse model (Cristina et al. 2006). In the pituitary of Drd2
-/-
 female 602 
mice, prolactinomas gradually develop starting from 6-8 months of age, as visible by MRI and after 603 
necropsy (Supplementary Fig. S7A). The CD31¯/CD45¯ SP (pSP) proportion in the tumor-bearing AP 604 
from Drd2
-/- 
mice (1.7% ± 0.3; n=5; Supplementary Fig. S7B) is higher than from heterozygous Drd2
+/-
 605 
(1.4% ± 0.6; n=2) and wildtype Drd2+/+ control littermates (1.3% ± 0.2; n=2). Calculated to absolute 606 
cell numbers (see Materials and Methods), the Drd2
-/-
 AP contains about 10-fold more pSP cells than 607 
the control mice (Fig. 5A). Similarly, the absolute number of colony-forming cells (also often used to 608 
in-vitro investigate TSC activity) is higher in Drd2
-/-
 than Drd2
+/-
 pituitaries (3.9-fold ± 0.7; n=3). In 609 
addition, colonies that develop from the Drd2-/- pituitary are generally larger in size and more 610 
smoothly shaped than the colonies from the heterozygous mice (Supplementary Fig. S7C). 611 
We next examined the prolactinoma-bearing pituitary of Drd2
-/-
 mice for Sox2
+
 cells. From 612 
countings in dissociated APs (see Materials and Methods), the absolute number of Sox2+ cells is 613 
higher in the Drd2
-/-
 AP when compared to the wildtype gland (2.4-fold ± 0.6; n=3) (Fig. 5B). At least 614 
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part of the increase in Sox2+ cells is due to higher proliferative activity; whereas proliferating (Ki67+) 615 
Sox2
+
 cells are virtually absent in wildtype Drd2
+/+
 AP at the ages tested (6 to 12 months), double 616 
Sox2
+
/Ki67
+
 cells are more readily observed in Drd2
-/-
 AP (Fig. 5C). Furthermore, as also seen before 617 
(Chen et al. 2009; Fu et al. 2012; Gremeaux et al. 2012), Sox2-immunoreactive signal is not only 618 
found in the expected location of the nucleus (nuclear-Sox2
+
 or nSox2
+
 cells), but some cells show 619 
Sox2+ signal in the cytoplasm (cytoplasmic-Sox2+ or cSox2+ cells). The Drd2-/- cSox2+ cells show a 620 
higher increase than the nSox2
+
 cells when compared to Drd2
+/+
 wildtype pituitaries (3.1-fold ± 0.3 621 
and 2.3-fold ± 0.7, respectively; Fig. 5B-C). In situ, Sox2+ cells in the Drd2-/- pituitary are found in the 622 
marginal zone bordering the cleft, which is not different from wildtype (Fig. 5D and Supplementary 623 
Fig. S7D). On top of this location, frequent clusters of Sox2
+
 cells are observed within the PRL
+
 tumor 624 
cell mass in the Drd2-/- pituitary (Fig. 5D and Supplementary Fig. S7D). In the wildtype gland, Sox2+ 625 
cell clusters are also observed spread within the endocrine AP parenchyma (Fig. 5D and 626 
Supplementary Fig. S7D). Double Sox2+/PRL+ cells were not observed in neither of the pituitary 627 
phenotypes. Taken together, the number of Sox2
+
 cells clearly increases in Drd2
-/-
 versus wildtype 628 
pituitary, but their overall appearance in the putative stem cell niches seems not very different. 629 
630 
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DISCUSSION 631 
Adenomas represent the most frequent pathology of the pituitary gland. Despite extensive 632 
research, not much is known about the mechanisms underlying pituitary tumor pathogenesis. 633 
In the present study, we demonstrate the existence of a SP in different models of pituitary 634 
tumor including human adenomas, mouse tumors and cell lines. During the last decade, a SP has 635 
been identified in many tumor types and cell lines, and was often found enriched in cells with CSC or 636 
CSC-like phenotype or activity (Patrawala et al. 2005; Wu & Alman 2008; Kato et al. 2010; Britton et 637 
al. 2012; Moti et al. 2014). The majority of these studies looked for CSC in malignant cancers. Our 638 
study is among the first to identify a SP in benign tumors (Wu et al. 2007) . The pituitary adenoma SP 639 
still represents a heterogeneous population, similar to the SP in other tumors as well as in healthy 640 
tissues (Pfister et al. 2005; Uezumi et al. 2006). In a previous study we also detected endothelial-type 641 
cells in the SP of the normal (mouse) pituitary; further purification led to the identification of 642 
pituitary stem cells (Chen et al. 2009). The endothelial-type SP cells of the pituitary tumors may 643 
represent a progenitor phenotype, driving angiogenesis during tumor expansion. Presence of 644 
endothelial progenitor cells in pituitary adenomas has indeed been suggested based on detection of 645 
CD133, CD34, NESTIN and VEGFR2 in non-hormonal and non-folliculostellate cells of the tumors 646 
(Yunoue et al. 2011). Of note, the expression picture distilled from the total adenoma SP was found 647 
to be largely reconfirmed in the purified CD31¯/CD45¯ SP (pSP). Also other studies have 648 
demonstrated that expression characteristics of minority CSC fractions can already surface in still 649 
mixed populations (Eppert et al. 2011). 650 
Several genes upregulated in the (p)SP are associated with a ‘tumor stemness’ phenotype as 651 
also reported for the SP in other tumors (Patrawala et al. 2005; Wu & Alman 2008; Kato et al. 2010; 652 
Britton et al. 2012; Moti et al. 2014). In addition, the NOTCH, WNT and TGFβ/BMP pathways 653 
represent not only ‘(tumor) stemness’ signaling systems but also regulatory circuits well known for 654 
their critical role in pituitary embryonic development (Zhu et al. 2007; Vankelecom 2010). Also the 655 
upregulated expression of NOTCH2 may be remarkable in this sense because particularly this 656 
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member of the Notch receptor family is highly expressed in the progenitor cells of Rathke’s pouch, 657 
the embryonic pituitary anlage (Zhu et al. 2007; Vankelecom 2010). This embryonic link may be in 658 
line with the idea that CSC recapitulate aspects of embryonic development. Also other studies 659 
suggested the involvement of NOTCH and WNT signaling in pituitary tumorigenesis as concluded 660 
from transcriptomic analysis of unfractionated adenomas (Moreno et al. 2005). Furthermore, the 661 
upregulation of HIF2α in the SP may be of importance; in other tumors like glioma, HIF2α regulates 662 
the tumorigenic capacity of the CSC fraction (Das et al. 2008). Hypoxia is known to stimulate CXCR4 663 
expression (De Craene & Berx 2013)  which is indeed found upregulated in the pituitary tumor (p)SP. 664 
In many cancer types CXCR4 has been advanced as a marker of CSC, and the pathway is known to 665 
play a role in CSC activity (Hermann et al. 2007; Vankelecom & Gremeaux 2010; Clevers 2011). Of 666 
further note, the epidermal growth factor receptor-associated protein-8 (EPS8) is also overexpressed 667 
in the pSP (4 of the 5 adenomas, p<0.05; Supplementary Table S8). This oncoprotein has previously 668 
been found upregulated in multiple pituitary tumor subtypes in which it mediates survival, 669 
proliferation and tumorigenicity (Xu et al. 2009a). Moreover, the accompanying receptor EGFR is also 670 
upregulated and is involved in tumor cell migration in some cancers (Hölsken et al. 2011). Finally, our 671 
expression data suggest that the PI3/Akt/mTOR/PTEN pathway is also enriched in the adenoma SP 672 
(data not shown). This pathway has been proposed to play a role in pituitary tumorigenesis 673 
(Dworakowska et al. 2009). Moreover, CXCR4 and PI3K/Akt are interconnected; it has been shown 674 
that paracrine/autocrine activation of CXCR4 signaling provokes Akt-mediated prosurvival of 675 
glioblastoma CSC (Rubin et al. 2003; Gatti et al. 2013). 676 
It should be noticed that the expression pattern in the pSP does only minimally overlap with the 677 
set of genes (CD133, NESTIN, CD90/THY1, OCT4, MSI, JAG2, NOTCH4, DLL1) recently identified as 678 
upregulated in candidate pituitary TSC (so-called ‘pituitary adenoma stem-like cells’ or PASCs), which 679 
were obtained by sphere-like culture (Xu et al. 2009b). In our study, only NOTCH4, DLL1 and NESTIN 680 
are found overexpressed, with NOTCH4 and DLL1 only upregulated in the total SP and not in the pSP. 681 
Moreover, expression levels of the multidrug transporter genes BCRP1 (ABCG2) and MDR1 (ABCB1) 682 
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were reported not to be upregulated in the PASCs (Xu et al. 2009b). These divergent results may be 683 
mainly explained by the use of cultured cells (Xu et al. 2009b) versus cells obtained directly from the 684 
tumor (present study) (further commented on in Vankelecom 2012; Vankelecom & Chen 2014). 685 
In a recent study (Donangelo et al. 2014), candidate TSC were proposed to exist in pituitary 686 
tumors developing in Rb
+/−
 mice. These tumors differ from typical pituitary adenomas (i.e. of the AP) 687 
since arising in the intermediate lobe (IL) of the gland. Stem cell antigen 1 (Sca1)-immunoreactive 688 
cells sorted from these IL tumors showed higher sphere-forming capacity when compared to the 689 
Sca1- cells, as well as increased expression of Sox2 and nestin, and tumor-growth advantage after 690 
injection of a high number of cells (105) into the brain striatum of NOD-SCIDIL2Rγ-/- mice. Before, we 691 
have shown that pituitary ‘stemness’ is rather accompanied by the absence of Sca1 and that Sca1 692 
expression is mainly found in the endothelial fraction of the SP (Chen et al. 2009), later supported by 693 
the detection of Sca1 in progenitor cells of endothelial or mesenchymal origin in mouse pituitary cell 694 
lines (Mitsuishi et al. 2013). Thus, Sca1 expression may represent a difference in the signature of the 695 
IL tumor TSC and the normal pituitary stem cells. Alternatively, Sca1
+
 cells from the IL tumors may 696 
also include endothelial progenitor cells (CD31+ cells were not removed from the Sca1+ fraction) 697 
which would facilitate tumor xenograft development by providing angiogenic support, and which 698 
may be an (additional) explanation for the tumor-growth advantage. Similar to our findings, the 699 
Sca1+ fraction did not fully retrieve the tumorigenic activity and Sca1- cells also formed tumors 700 
(although to a lower extent). Intriguingly, in the majority of the xenograft tumors derived from the 701 
Sca1+ cell population, no Sca1+ cells could be detected anymore, which does not exactly fit with the 702 
definition of self-renewing CSC. It should also be remarked that Sca1 cannot be employed as a 703 
(potential) TSC marker in human pituitary adenomas since this gene (product) does not exist in man. 704 
In contrast to the highly penetrant Rb+/
− IL tumors (Donangelo et al. 2014), benign human 705 
pituitary adenomas (transplanted sc or subrenally) did not expand in mice whatever the mouse grade 706 
of immunodeficiency. Xu et al. (2009b) reported ‘growth and reconstitution of the original tumor’ 707 
from their PASC spheroids (as analyzed for 1 GH-A) when implanted in the forebrain of NOD/SCID 708 
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mice, but no clearly demarcated tumor or expansion was shown (further reviewed in Vankelecom 709 
2012; Vankelecom & Chen 2014). 710 
Since the standard xenograft assay did not work starting form benign human pituitary adenoma, 711 
we further turned to in vitro TSC assays and to the well-established pituitary tumor AtT20 cell line. 712 
Cultured cell lines are often used as complementary paradigms to study (candidate) CSC. Moreover, 713 
in cell lines of multiple cancer types, the SP has been found to enrich for authentic or candidate CSC 714 
(Patrawala et al. 2005; Wu & Alman 2008; Kato et al. 2010; Britton et al. 2012). First, we discovered 715 
that human pituitary adenomas contain self-renewing sphere-forming cells that express the 716 
stemness markers Sox2 and nestin, and that the sphere-initiating cells segregate to the pSP. In 717 
addition, the AtT20 cell line also contains a SP which was found to enrich for cells that are more 718 
tumorigenic (i.e. grow faster and larger tumors) than MP cells, that better reconstitute the tumor’s 719 
original heterogeneity (SP/MP profile) - a further property of CSC -, and that express CSC-associated 720 
genes. The segregation of tumorigenic activity in the SP is not absolute as also observed in various 721 
other studies on CSC (Boumahdi et al. 2014; Vanner et al. 2014) and in the Rb
+/-
 IL tumors as 722 
mentioned above (Donangelo et al. 2014). 723 
The (p)SP identified also displays an expression pattern supportive of EMT occurring in that 724 
tumor compartment. In recent studies, CSC and EMT have been linked in that EMT acts as a major 725 
driver of CSC generation and activity (Mani et al. 2008; Morel et al. 2008; Kong et al. 2010; Pirozzi et 726 
al. 2011; Yoon et al. 2012; De Craene & Berx 2013). In addition to being an argument in favor of the 727 
CSC(-like) phenotype of the pSP, the detection of EMT may also have implications for understanding 728 
pituitary tumor behavior. In several cancers, EMT, or EMT-driven CSC, are involved in expansion, 729 
invasion, resistance to hostile conditions (including therapy) and recurrence (Mani et al. 2008; Morel 730 
et al. 2008; Bertran et al. 2009; Kong et al. 2010; Pirozzi et al. 2011; De Craene & Berx 2013). The GO 731 
enrichment picture including gene clusters associated with cell motility and migration, as well as the 732 
expression of chemotactic receptors like CXCR4 in the adenoma pSP further supports the migratory 733 
capacity. Noteworthy, highest relative expression levels in the pSP (and highest differences in pSP 734 
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versus pMP) of the EMT-associated genes ZEB2, SNAI2 and TWIST1 were found in the adenoma 735 
sample with the most aggressive character regarding invasion of neighbouring structures (PA 40 in 736 
Table 1). On the other hand, from the data of a limited number of tumors assessed for invasive 737 
character (i.e. PA03, 06, 07, 10, 15, 17, 19, 20, 22, 23, 33, 34, 35, 38, 40), no correlation emerged 738 
(yet) between invasiveness and SP proportion. The pSP compartment also expresses angiogenic 739 
factors which may suggest that TSC drive tumor angiogenesis to support the growth of the tumor. 740 
CSC may also contribute to neovascularization through transdifferentiation to endothelial cells as has 741 
been reported in glioblastoma (Dong et al. 2011). Processes such as EMT, angiogenesis and hypoxia 742 
are known to contribute to maintenance and regulation of CSC in interaction with their 743 
microenvironment. 744 
Because human pituitary adenoma fails to grow not only in vivo but also in vitro (Hofland & 745 
Lamberts 2002), EMT was further studied in the AtT20 cell line. The TGFβ pathway is known as an 746 
important regulator of EMT (Bertran et al. 2009; Pirozzi et al. 2011; De Craene & Berx 2013). 747 
Although TGFβ activation stimulated expression of some EMT-regulatory and ‘stemness’-associated 748 
genes, treatment of AtT20 did not enhance EMT-linked cell motility, neither did pretreatment induce 749 
faster or more pronounced xenograft tumor formation. Of note, the impact of the in vitro 750 
pretreatment may fade away during in vivo growth. In general, TGFβ is known to play a dual role in 751 
tumor pathogenesis: it may not only promote tumor progression (angiogenesis, invasion, metastasis) 752 
by stimulating tumorigenic activity and EMT (Mani et al. 2008; Bertran et al. 2009; Pirozzi et al. 2011; 753 
De Craene & Berx 2013) but may also inhibit tumor growth by reducing cell proliferation (Ramsdell 754 
1991; Tirino et al. 2013). We indeed observed a small tendency towards slower tumor growth after 755 
pretreatment of the AtT20 cells with TGFβ1 (see Supplementary Fig. S5C). Furthermore, it should be 756 
mentioned that AtT20 cells already display some mesenchymal character in basal conditions as 757 
concluded from their spindle-shaped morphology and their basic motility in the scratch assay (data 758 
not shown), which may explain the limitation to supplementarily activate a mesenchymal phenotype. 759 
Regarding the CXCR4 pathway as the second EMT-regulatory system tested, inhibition leads to 760 
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reduction of AtT20 cell motility and of tumor growth. The latter finding is in line with a previous 761 
study showing that anti-CXCR4 treatment suppresses primary brain tumor growth, and that 762 
treatment of mice with AMD3100 results in decreased proliferation and invasion of the xenografted 763 
brain tumors, and in better survival of the animals (Rubin et al. 2003). In addition, activation of 764 
CXCR4 has been shown to stimulate cell proliferation in human pituitary adenoma cultures (Barbieri 765 
et al. 2008). Here, we show that the Cxcr4 pathway is involved in pituitary tumor growth in vivo. 766 
AMD3100 was found to induce AtT20 cell death and apoptosis, and to reduce cell proliferation (as 767 
analyzed in vitro), similar to findings by others in pituitary and other tumors (Barbieri et al. 2008; 768 
Gatti et al. 2013). Whether EMT is (also) implicated in the growth-inhibitory effect of AMD3100, is 769 
not clear yet; expression of the tested selection of EMT genes was not affected after long-term 770 
treatment in vivo (20 days) or short-term exposure in vitro (72 hr). EMT-associated genes different 771 
from the ones analyzed may still be involved (as e.g. described in breast CSC; Yoon et al. 2012). 772 
Neither activation of the TGFβ pathway nor inhibition of the Cxcr4 pathway significantly affected the 773 
SP proportion, although effects may be small and absence of an effect on proportion does not 774 
exclude a possible effect on the (molecular) activation status of the SP cells. Further studies are 775 
needed to shed more light on the mechanisms. 776 
An important question in cancer research concerns the link of tumorigenesis (and CSC) with the 777 
tissue’s own stem cells. In several types of cancer, it has been shown that tissue stem cells are at the 778 
origin of tumors and/or of CSC (Barker et al. 2009; Llaguno et al. 2009; Zhu et al. 2009; Mulholland et 779 
al. 2010; Lapouge et al. 2011; Chen et al. 2012; Schepers et al. 2012; Boumahdi et al. 2014; Vanner et 780 
al. 2014). On the other hand, stem cells may not directly be involved, but may become activated 781 
when a tumorigenic ‘assault’ is occurring in their tissue (Vankelecom & Gremeaux 2010; Vankelecom 782 
& Chen 2014). Here, we observed that the pSP, the Sox2
+
 and the colony-forming cells are increased 783 
in number when tumors are present in the pituitary, as analyzed in Drd2-/- mice in which 784 
prolactinomas develop within their natural microenvironment. Our findings suggest activation of the 785 
pituitary stem cell compartment during tumorigenesis with a rise in cell number. It should be noted 786 
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that the populations identified may comprise both the ‘normal’ pituitary stem cells and the 787 
(potentially stem cell-derived) TSC or TSC-like cells. At present, it is not possible to distinguish 788 
between both on the basis of the properties analyzed (SP, Sox2 expression, colony formation). The 789 
fact that cell numbers and increments are not identical among the 3 populations (pSP, Sox2+ and 790 
colony-forming) suggests that they do not fully overlap, as has also been observed before (Chen et al. 791 
2009; Fu et al. 2012). Moreover, more than one (cancer) stem cell population has also been detected 792 
in other tissues and tumors (see e.g. Zhu et al. 2014). The finding that these populations expand in 793 
number may indicate that the stem cells react during tumorigenesis and that they may play a role in 794 
the pathogenic process. Of note, the higher increase in cytoplasmic-Sox2+ cells in the tumorous 795 
pituitary might support a higher differentiation rate towards tumor PRL
+
 cells (Chen et al. 2009; Fu et 796 
al. 2012; Gremeaux et al. 2012). In addition, Sox2+ cell clusters were often observed within the PRL+ 797 
tumor cell masses, although they also occur scattered over the parenchyma in the normal AP. 798 
Whether existing clusters are entrapped during tumor formation, or whether they play a more active 799 
role in the tumorigenic process, either directly (as origin) or indirectly (as tumor-inducing or -tropic), 800 
needs to be further clarified (e.g. by lineage tracing). In a recent study, lineage tracing did not detect 801 
a direct link of descent between transgenically Wnt/β-catenin-induced craniopharyngioma in the 802 
pituitary and the Sox2+ stem cells. Instead, findings suggested that the Sox2+ stem cells rather act as 803 
paracrine tumor-activating cells (Andoniadou et al. 2013). Adamantinomatous craniopharyngioma is 804 
a typically pediatric tumor likely originating from ectopic remnants of Rathke’s pouch, and thus 805 
different from the typical AP tumors. The transcription factor Sox2 itself may also play a role in 806 
pituitary tumorigenesis, e.g. when not properly shut down by the tumor suppressor p27 (at least as 807 
demonstrated for IL tumors; reviewed in Vankelecom and Chen, 2014). In addition, Sox2 can act as 808 
an oncogene in tissues where it is expressed in the putative stem cells (e.g. lung, oesophagus and 809 
skin) (Arnold et al. 2011; Boumahdi et al. 2014). Also overexpression of other pituitary stem cell 810 
factors (like Prop1) from the early Rathke’s pouch state onwards, may lead to tumor formation in the 811 
gland (reviewed in Vankelecom and Chen, 2014). Again, Prop1 is not found within the tumors but in 812 
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non-neoplastic regions surrounding the lesions, suggesting that Prop1 overexpression does not 813 
generate tumor-driving stem cells but rather trophically supporting cells. 814 
In conclusion of our study, we identified a SP in pituitary tumor displaying TSC-associated 815 
molecular and functional characteristics. Identification of this cell population may eventually help to 816 
better understand pituitary tumor pathogenesis, and may have an impact on clinical management of 817 
the disease. The global molecular profile of the pSP may thereby serve as a valuable source to 818 
identify potentially interesting therapeutic targets for further examination. 819 
820 
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FIGURE LEGENDS 
Fig. 1. Identification and characterization of the side population (SP) in human pituitary 
adenomas 
(A) Dot plots of dual-wavelength FACS analysis of human pituitary adenoma cells after 
incubation with Hoechst33342 alone (left), or together with verapamil (right). The SP (black) and 
MP (white) are gated and SP proportions are indicated. A representative example is shown. 
(B) Boxplot of SP proportions obtained from NF-A (n=33) and GH-A (n=20) as well as from all 
samples taken together (n=60). Minimum and maximum values (whiskers) and outliers (dots) 
are indicated. 
(C) Dot plots of FACS analysis of human pituitary adenoma cells after incubation with 
Hoechst33342 and immunostaining for CD31 and CD45. The CD31
+
, CD45
+
 and CD31¯/CD45¯ 
cells within the SP are also shown (inset). 
(D) Percentage of CD31+ (upper panel) and CD45+ cells (lower panel) within the SP versus the SP 
proportion within the pituitary adenomas analyzed (n=37 and 31, respectively). 
(E) Expression analysis by RT-qPCR of a selection of markers identified as differentially expressed 
in the pituitary adenoma CD31
-
/CD45
-
 SP (pSP) versus the pMP by microarray analysis. Bars 
indicate mean of fold expression pSP/pMP ± SEM (n=7 pituitary adenomas); *, p<0.05. 
 
Fig. 2. Human pituitary tumors contain sphere-forming cells segregating to the pSP 
(A) Smooth-edged spheres (arrows) develop in cultures of total pituitary adenoma cells, clearly 
distinct from clumps of cells sticking together (arrowheads). 
(B) Examples of spheres at higher magnification. 
(C) Spheres (arrow) show Sox2 immunofluorescent signal (red) whereas clumps do not 
(arrowheads). Nuclei are stained with ToPro3. A representative example is shown (left: light-
microscopic image; right: overlay). 
(D) Secondary spheres (arrows) form after re-seeding the dissociated primary sphere cells. 
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(E) Example of a secondary sphere at higher magnification. 
(F) Third-generation spheres (arrow) develop after re-seeding the dissociated second-generation 
sphere cells. 
(G) Spheres develop from pSP cells of pituitary adenoma, although their number is low. In pMP 
cell cultures, only clumps of cells are observed (inset). 
All pictures were taken at 7 days of culture. Scale bar: 50μm. 
 
Fig. 3. Identification and characterization of the SP in the AtT20 pituitary tumor cell line 
(A) Dot plots of dual-wavelength FACS analysis of AtT20 cells after incubation with 
Hoechst33342 alone (left), or together with verapamil (right). The SP (black) and MP (white) are 
gated and SP proportions are indicated. A representative example is shown. 
(B) Cd44 and Cxcr4 gene expression in the SP and MP of AtT20 cells in culture, as determined by 
RT-qPCR. Bars show mean of fold SP/MP ± SEM (n=3); *, p<0.05. 
(C) Volume of xenograft tumors grown in SCID mice as measured at day 40 (d40) and d47 after 
sc injection of the indicated number of AtT20 SP cells (black) and MP cells (grey). Bars show 
mean ± SEM (5 mice for 10 000 cells, and 4 mice for 5000 and 1000 cells; injected in 2 or 3 
independent experiments; see Supplementary Fig. S5B); *, p<0.05. 
 
Fig. 4. Involvement of the TGFβ and Cxcr4 pathways in EMT-/TSC-associated properties of the 
AtT20 pituitary tumor cell line 
(A) Gene expression in TGFβ1-treated (72 hr) and -untreated AtT20 cells as determined by RT-qPCR. 
Bars show mean of fold TGFβ1/control ± SEM (n=3); *, p<0.05. 
(B) Effect of TGFβ1 and AMD3100 on the motility of AtT20 cells. Light-microscopic pictures of the 
AtT20 cell culture after applying a scratch ‘wound’, treated or not (control) with TGFβ1 or AMD3100 
for the indicated time period. Representative examples are shown. Scale bar: 100µm. The ‘% open 
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area’ was determined with TScratch software in the cultures without compound (black), or with 
TGFβ1 (grey) or AMD3100 (dark grey). Bars show mean ± SEM (n=4); *, p<0.05. 
(C) Effect of the Cxcr4-antagonist AMD3100 on AtT20 tumor growth. Immunodeficient SCID mice 
with growing AtT20-derived sc tumors were treated with intratumoral injections of AMD3100 (grey) 
or vehicle (PBS; black) starting from day 21 (arrow) after sc AtT20 cell implantation. Volumes of 
individual tumors are shown, with horizontal line indicating the mean of each group at each time 
point (n=3, with an initial number of 5 mice per independent experiment, a number declining 
towards d35-42 because of gradual decease of mice); *, p<0.05. 
(D) Gene expression in AMD3100-treated (20 days) and -untreated AtT20 xenograft tumors as 
determined by RT-qPCR. Bars show mean of fold AMD3100/control ± SEM (n=3 except for Snai1 
and Snai2 where n=2); *, p<0.05. 
(E) Effect of AMD3100 on AtT20 cell viability. Percentage of dying/dead AtT20 cells (as 
determined by trypan blue exclusion) after treatment with AMD3100 (grey) or vehicle (black). 
Bars show mean ± SEM (n=3); *, p<0.05. 
(F) Effect of AMD3100 on AtT20 cell apoptosis. Percentage of TUNEL
+
 cells after treatment with 
AMD3100 (grey) or vehicle (black). Bars show mean ± SEM (n=3); *, p<0.05. 
(G) Effect of AMD3100 on AtT20 cell proliferation. Percentage of Ki67
+
 AtT20 cells after 
treatment with AMD3100 (grey) or vehicle (black). Bars show mean ± SEM (n=3); *, p<0.05. 
 
Fig. 5. Pituitary stem cells in the Drd2-/- pituitary tumor model 
(A) Fold difference in absolute number of pSP cells in the anterior pituitary (AP) of homozygous  
Drd2
-/-
 (n=5) and heterozygous Drd2
+/-
 mice (n=2), relative to wildtype Drd2
+/+
 mice (set as 1). *, 
p<0.05 versus Drd2
+/+
 mice. 
(B) Absolute number of Sox2
+
 cells in the AP of homozygous Drd2
-/-
, heterozygous Drd2
+/-
 mice and 
wildtype Drd2
+/+
 mice. Bars represent mean ± SEM (n=3), with indication of the nuclear-Sox2
+
 cells 
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(black segment) and the cytoplasmic-Sox2
+
 cells (grey segment). *, p<0.05 versus Drd2
+/+
 mice (for 
total Sox2
+
 cell number). 
(C) Immunofluorescent staining of dissociated AP cells (cytospins) from wildtype Drd2+/+ mice 
(upper panel) and homozygous Drd2
-/-
 mice (middle and lower panels) for Sox2 (red) and Ki67 
(green). Double Sox2
+
/Ki67
+
 cells are indicated (arrows). Nuclei are stained with DAPI. 
Representative examples are shown (female mice, 10-12 months of age). Scale bar: 50μm. 
(D) Confocal images of pituitary vibratome sections of Drd2-/-, Drd2+/- and wildtype Drd2+/+ mice 
immunofluorescently stained for Sox2 (red) and prolactin (PRL, green). Representative examples 
are shown (female mice, 10-13 months of age). In all mouse phenotypes, Sox2
+
 cells are found in 
the marginal cell layer along the cleft. In Drd2
-/-
 pituitary Sox2
+
 cells clustered in small groups are 
often observed within the PRL
+
 tumor cell mass (arrows), but clusters of Sox2
+
 cells are also 
found scattered in the anterior pituitary (AP) parenchyma of control Drd2
+/-
 and Drd2
+/+
 mice. 
Nuclei are stained with ToPro3. Scale bar: 50μm. Insets show a lower-magnification overview. IL, 
intermediate lobe. 
 
 
SUPPLEMENTARY FIGURE LEGENDS 
Fig. S1. Characterization of the side population (SP) in human pituitary adenomas 
(A) Boxplot of SP proportions measured in pituitary adenoma samples immediately after surgical 
resection (Fresh; n=24) or after cryopreservation and thawing (Frozen; n=36). Minimum and 
maximum values (whiskers) and outliers (dots) are indicated. 
(B) Forward scatter (FSC) and side scatter (SSC) of the adenoma SP cells (blue) compared to the 
MP cells (orange), both as gated in Fig. 1A. 
(C) Principal Component analysis (PCA) of whole-genome expression data. A graphic is provided 
illustrating the distribution of the 9 micro-arrayed SPs (grey) and MPs (black) of pituitary 
adenomas along 2 principal components (as defined by Agilent’s Feature Extraction Software).  
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(D) Hierarchical clustering of whole-genome expression data. Upper panel: schematic representation 
of gene expression levels in adenoma SP versus MP and resultant hierarchical clustering, using the 
probe sets (2760) identified as differentially expressed in the less stringent protocol (see Materials 
and Methods). Lower panel: schematic representation of gene expression levels in adenoma SP 
versus MP and resultant hierarchical clustering, using the probe sets (334) identified as differentially 
expressed in the more stringent approach (see Materials and Methods). Expression levels are 
indicated on a continuous color scale from downregulated (green) to upregulated (red) in the SP 
versus the MP. The SP samples are indicated by grey dots and the MP samples by black dots, as 
shown under each heat map. 
 
Fig. S2. Genes differentially expressed between CD31¯/CD45¯ SP (pSP) and CD31¯/CD45¯ MP 
(pMP) from human pituitary adenomas 
(A) Volcano plot (log2-ratio versus minus log10 p-value) of whole-genome expression data from 
the pSP and pMP of human pituitary adenomas (n=5). Statistically upregulated genes (cut-off: 
fold-change ≥2 and uncorrected p<0.001; see Materials and Methods) are indicated in red, 
downregulated genes in green. It should be noted that many genes are scored altered by the 
fold-change criteria but not statistically significant because of the still relatively small number of 
samples analyzed. 
(B) MA plot (average intensity versus log2-ratio) of whole-genome expression data from the pSP 
and pMP of human pituitary adenomas (n=5). Statistically upregulated genes as determined in 
the Volcano plot are indicated in red, downregulated genes in green. 
(C) Name of the microarray probes statistically upregulated (left; red) or downregulated (right; 
green) in the pSP versus pMP, as extracted from the Volcano plot. 
(D) Immunohistochemical analysis of E-cadherin, vimentin, IL-6 and NOTCH2 in paraffin-
embedded pituitary adenoma sections. Immunostaining for E-cadherin shows several 
immunonegative patches. Vimentin, IL-6 and NOTCH2 are found in some tumor cells (arrows), 
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either alone or in clusters. Vimentin is also present in pericapillar cells (arrowheads). Scale bar: 
50 μm. 
 
Fig. S3. Expression of stemness markers in spheres from human pituitary tumors 
(A-B) Immunofluorescent analysis of spheres from human pituitary adenomas at day 7 of 
culture for SOX2 (red; A) or nestin (green; B). Nuclei are stained with ToPro3. Representative 
examples are shown (left: light-microscopic image; right: overlay). 
(C) Immunofluorescent analysis of spheres from a human GH-A at day 8 of culture for SOX2 
(red; A) and GH (green; B). Some sphere cells express the hormone produced by the original 
tumor (here, GH). 
Scale bar: 50μm. 
 
Fig. S4. Pituitary adenoma after transplantation under the kidney capsule 
(A) H&E staining 6 months after transplantation of pituitary adenoma fragments under the 
kidney capsule of an immunodeficient SCID mouse, showing renal tissue (pink) and viable 
tumor tissue (arrows). 
(B) Enlargement of the boxed area in A, showing the pituitary adenoma structure. 
Scale bar: 50µm. 
 
Fig. S5. Tumor growth from AtT20 and effect of TGFβ1 
(A) AtT20 cells (5x105) were sc injected into SCID mice. Individual tumor volumes are shown, 
with horizontal line indicating the mean of each group at each time point (n=2, with an initial 
number of 4 mice per independent experiment). 
(B) AtT20 SP (black) and MP (grey) were sc injected into SCID mice at the indicated number of 
cells (10 000, 5000 or 1000). Individual tumor volumes are shown, with horizontal line indicating 
the mean of each group at each time point (n=5 mice for 10 000 cells, n=4 mice for 5000 and 
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1000 cells; injected in 2 or 3 independent experiments); *, p<0.05. Some examples of dissected 
xenograft tumors are shown. 
(C) AtT20 cells were pretreated with TGFβ1 or vehicle for 72 hr and then sc implanted in SCID 
mice. Individual tumor volumes are shown, with horizontal line indicating the mean of each 
group at each time point (n=3, with an initial number of 5 mice per independent experiment). 
 
Fig. S6. Expression of the pituitary stem cell marker Sox2 in pituitary tumor cell lines 
(A) Sox2 gene expression in the SP and MP from the AtT20 cell line and from the rat 
lactosomatotrope GH3 cell line as determined by RT-qPCR. Bars show mean fold SP/MP  ± SEM 
(n=3); *, p<0.05. 
(B) Dot plots of dual-wavelength FACS analysis of the GH3 cell line after incubation with 
Hoechst33342 alone (left), or together with verapamil (right). The SP (black) and MP (white) are 
gated and SP proportions are indicated. A representative example is shown. 
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Fig. S7. Pituitary stem cells in the Drd2
-/-
 pituitary tumor model 
(A) Transversal MRI pictures of the head of a female heterozygous Drd2+/- (upper left panel) and 
homozygous Drd2
-/-
 (lower left panel) mouse at 8 months of age. The boxed region shows the 
pituitary, clearly bigger in the Drd2
-/-
 mouse. Photographs of the pituitary in situ after 
euthanasia and removal of the brain in a heterozygous Drd2
+/-
 (upper row) and homozygous 
Drd2
-/-
 (lower row) mouse at 14 months of age. The pituitary of the Drd2
-/-
 mouse is clearly 
bigger and contains large tumorous nodules. Scale bar: 1mm. 
(B) Dot plots of dual-wavelength FACS analysis of Drd2
-/-
 anterior pituitary (AP) after incubation 
with Hoechst33342 alone (left) or together with verapamil (right), and immunostained for CD31 
and CD45. The SP (black) and MP (white) are gated and SP proportions are indicated. CD45
+
, 
CD31
+
 and CD31
-
/CD45
-
 cells within the SP are shown (inset). A representative example is given.  
(C) Phase-contrast pictures of representative colonies formed after 4 days from Drd2-/- and 
Drd2
+/-
 AP cells. Scale bar: 100µm. 
(D) Additional pictures of Sox2 (red) and PRL (green) immunofluorescent staining in vibratome 
(A’-E’) and paraffin-embedded (F’ and G’) sections of Drd2
-/-
, Drd2
+/-
 and wildtype Drd2
+/+
 
pituitaries (female mice, 10-13 months of age). In all mouse phenotypes, Sox2
+
 cells are found in 
the marginal cell layer along the cleft. In Drd2
-/-
 pituitary, Sox2
+
 cells clustered in groups are 
often observed within the PRL
+
 tumor cell mass (B’, arrows). Clusters are sometimes large in size 
(F’ with blow-up in G’). Cytoplasmic-Sox2
+
 cells are more abundant in Drd2
-/-
 than control 
pituitaries (arrowheads). 
Nuclei were stained with ToPro3 (A’-E’) or DAPI (F’ and G’). Scale bar: 50μm. Insets show a 
lower-magnification overview. AP, anterior pituitary; IL, intermediate lobe. 
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Table 1. Summary of clinical and experimental data of the pituitary adenoma samples analyzed 
Pituitary Adenoma 
(PA) sample 
number 
Gender 
Age at 
time of 
surgery 
(yr) 
PA 
phenotype
a
 
Size
b
 
Fresh or 
cryopreserved 
SP 
(% of total cells) 
CD31
+
 
(% of SP) 
CD45
+
 
(% of SP) 
Micro-array 
RT-
qPCR 
IHH 
PA 01 M 62 NF-A Macro F 7.5 ND ND     
 
PA 02 M 41 NF-A Macro F 1.5 ND ND     
 
PA 03 M 46 GH-A Macro F 1.8 ND ND x   
 
PA 04 M 37 GH-A Macro F 1.4 ND ND     
 
PA 05 F 28 GH-A Macro F 1.8 ND ND     
 
PA 06 M 84 GH-A Macro F 1.4 ND ND x   
 
PA 07 F 76 GH-A Macro F 1.6 ND ND x   
 
PA 08 M 39 NF-A Micro F 2.0 ND ND     
 
PA 09 F 54 NF-A Macro F 2.7 ND ND     
 
PA 10 M 59 GH-A Macro C 2.3 ND ND x   
 
PA 11 F 59 GH-A Macro C 8.0 ND ND     
 
PA 12 M 71 GH-A Macro C 1.8 ND ND     
 
PA 13 F 44 ACTH-A Micro F 0.5 ND ND     
 
PA 14 F 72 NF-A Macro C 1.2 ND ND     
 
PA 15 M 79 NF-A Macro C 1.4 ND ND 
 
  
 
PA 16 M 72 GH-A Micro C 0.7 ND ND     
 
PA 17 M 35 NF-A Macro C 0.5 ND ND x   
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PA 18 F 43 GH-A Micro C 1.2 ND ND     
 
PA 19 F 57 NF-A Macro F 17.2 ND ND x   
 
PA 20 F 64 NF-A Macro F 1.5 ND ND x   
 
PA 21 F 48 ACTH-A Micro F 1.6 ND ND     
 
PA 22 F 77 NF-A Macro 
 
C 3.3 ND ND x   
Vim + 
IL-6 – 
Notch2 – 
PA 23 F 29 NF-A Macro F 0.6 ND ND x   
Vim + 
IL-6 + 
Notch2 + 
PA 24 F 60 GH-A Macro C 1.6 18.2 ND     
 
PA 25 F 19 NF-A Macro F 0.8 89.9 ND     
 
PA 26 M 43 NF-A Macro C 4.8 93.8 ND     
 
PA 27 M 40 NF-A Macro C 1.8 87.2 ND     
 
PA 28 F 34 GH-A Macro F 0.8 38.9 ND     
 
PA 29 F 54 NF-A Macro C 1.5 93.8 ND     
 
PA 30 F 42 NF-A Macro C 1.3 70 7.9     
 
PA 31 M 76 NF-A Macro C 0.7 84 3.4     
 
PA 32 M 62 GH-A Macro F 1.3 81.6 4.8     
 
PA 33 M 80 NF-A Macro F 0.6 23.6 1.7 x x 
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PA 34 M 70 NF-A Macro 
 
F 1.3 24 27.3 x x 
Vim + 
IL-6 – 
Notch2 + 
PA 35 M 40 NF-A Macro C 1.5 18.7 11.6 x x 
 
Vim – 
IL-6 – 
Notch2 – 
PA 36 M 62 NF-A Macro C 0.6 71.6 17.8     
 
PA 37 F 50 GH-A Micro C 1.8 57.5 6.7     
 
PA 38 M 70 NF-A Macro C 0.6 60.9 3.9 x x 
Vim + 
IL-6 + 
Notch2 + 
PA 39 F 39 PRL-A Macro C 1.2 43.3 33.5     
 
PA 40 M 63 NF-A Macro F 1.1 12.6 66.6 x x 
Vim + 
IL-6 + 
Notch2 + 
PA 41 M 39 NF-A Macro F 0.9 22 3.9     
 
PA 42 F 30 NF-A Macro C 0.5 13 40.4     
 
PA 43 M 61 GH-A Macro C 6.8 95.2 1.3     
 
PA 44 M 49 NF-A Macro F 0.6 33 35   x 
 
PA 45 M 63 NF-A Macro F 2.4 60 4     
 
PA 46 F 27 GH-A Macro C 0.6 23 33.5   x 
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PA 47 F 44 ACTH-A Micro  C 1.5 5.8 37.3   
  
PA 48 F 39 NF-A Macro C 1.2 43.3 33.5     
 
PA 49 M 66 NF-A Macro C 0.4 80.7 2.4     
 
PA 50 F 28 PRL-A Macro C 1.4 75.5 4.6     
 
PA 51 F 77 GH-A Macro C 0.5 12.7 0.2     
 
PA 52 F 74 NF-A Macro C 1.7 81.5 5.5     
 
PA 53 F 62 GH-A Macro C 1.5 5.8 37.3     
 
PA 54 F 62 GH-A Macro C 1.9 29.7 23     
 
PA 55 M 62 NF-A Macro C 0.6 63.6 1.4     
 
PA 56 M 46 NF-A Micro C 1.6 75.9 1.1     
 
PA 57 M 45 GH-A Macro C 1.9 29.7 23     
 
PA 58 M 46 GH-A  Macro C 1.9 29.7 23     
 
PA 59 M 52 NF-A  Macro C 0.8 86 4.3     
 
PA 60 M 65  NF-A  Macro C 0.5 48.4 1.1     
 
a
NF-A, non-functioning adenoma; GH-A, somatotropinoma, ACTH-A, corticotropinoma; PRL-A, prolactinoma. 
b
Size: micro-adenoma: <1cm (micro); macro-adenoma: ≥1cm (macro). 
ND, not determined; IHH, immunohistochemistry. 
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Table 2. Expression of a selection of genes in the total SP of human pituitary adenoma as 
concluded from microarray analysis 
Gene
a
 Gene description Expression in SP
b
 
(Tumor) stemness  
ABCB1 (MDR/TAP) ATP-binding cassette, sub-family B, member 1  
ABCG2 (BCRP1) ATP-binding cassette, sub-family G (WHITE), member 2  
CD44 CD44 molecule (Indian bloud group)  
CXCR4 Chemokine (C-X-C motif) receptor 4  
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  
KLF4 Kruppel-like factor 4 (gut)  
NES Nestin  
Notch pathway  
(and related) 
 
DLL1 Delta-like 1 (Drosophila)  
DLL3 Delta-like 3 (Drosophila)  
DLL4 Delta-like 4 (Drosophila)  
HES1 Hairy and enhancer of split 1 (Drosophila)  
HES2 Hairy and enhancer of split 2 (Drosophila)  
HES5 Hairy and enhancer of split 5 (Drosophila)  
HEYL Hairy/enhancer-of-split related with YRPW motif-like  
JAG1 Jagged 1  
NOTCH1 Notch 1  
NOTCH2 Notch 2  
NOTCH4 Notch 4  
TGFβ/BMP 
pathway  
(and related)  
 
BMP2 Bone morphogenetic protein 2  
BMP4 Bone morphogenetic protein 4  
BMP6 Bone morphogenetic protein 6  
MEN1 Multiple endocrine neoplasia 1  
SMAD2 SMAD family member 2  
SMAD3 SMAD family member 3  
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SMAD4 SMAD family member 4  
TGFB1 Transforming growth factor, beta 1  
TGFB2 Transforming growth factor, beta 2  
TGFBR2 Transforming growth factor, beta receptor 2  
TGFBR3 Transforming growth factor, beta receptor 3  
WNT/β-catenin 
pathway  
(and related) 
 
APC Adenomatous polyposis coli  
AXIN2 Axin 2  
CD44 CD44 molecule (Indian blood group)  
CDH1 E-cadherin (epithelial)  
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa  
DKK1 Dickkopf homolog 1 (Xenopus laevis)  
DKK2 Dickkopf homolog 2 (Xenopus laevis)  
FZD3 Frizzled family receptor 3  
FZD4 Frizzled family receptor 4  
FZD8 Frizzled family receptor 8  
LRP5 Low density lipoprotein receptor-related protein 5  
LEF1 Lymphoid enhancer binding factor 1  
MYC v-myc myelocytomatosis viral oncogene homolog (avian)  
WNT9B Wingless-type MMTV integration site 9B  
EMT  
 
Up in EMT 
CXCR4 Chemokine (C-X-C motif) receptor 4  
FN1 Fibronectin 1  
FOSL2 FOS-like antigen 2  
FOXC1 Forkhead box C1  
HOXB9 Homeobox B9  
KLF8 Kruppel-like factor 8  
MMP1 Matrix metallopeptidase 1 (interstitial collagenase)  
MMP2 Matrix metallopeptidase 2 (gelatinase A)  
SNAI1 Snail homolog 1 (Drosophila)  
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TCF4 Transcription factor 4  
VIM Vimentin  
ZEB1 Zinc finger E-box binding homeobox 1  
ZEB2 Zinc finger E-box binding homeobox 2  
Down in EMT   
CDH1 E-cadherin (epithelial)  
CLDN1 Claudin 1  
Angiogenesis/ 
endothelial  
 
CDH5 Cadherin 5, type 2 (vascular endothelium), VE-cadherin  
FLK1/KDR Kinase insert domain receptor (a type III receptor tyrosine kinase)  
PECAM1 (CD31) Platelet/endothelial cell adhesion molecule   
TEK/TIE2 Tyrosine kinase, endothelial  
TIE1 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1  
VCAM1 Vascular cell adhesion molecule 1  
VWF von Willebrand factor  
Immune/ 
hematopoietic  
 
CD45/PTPRC Protein tyrosine phosphatase, receptor type C  
 
a
Selection of genes as analyzed by microarray; genes are listed alphabetically per group. 
b
Expression level of the gene in the total adenoma SP: ( ) when >1.5-fold upregulated in the SP 
versus the MP in at least 2/3
rd
 of the adenoma samples analyzed (6 or more out of the 9); ( ) when 
>1.5-fold upregulated in the SP versus the MP in 5 out of the 9 adenoma samples; ( ) when >1.5-
fold downregulated in the SP versus the MP of at least 6 out of the 9 adenoma samples analyzed. 
Indicated as ( ) when <1.5-fold difference versus MP. 
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Table 3. Expression of a selection of genes in the pSP of human pituitary adenoma as concluded 
from microarray analysis 
Genea Gene description 
Expression in 
pSPb 
(Tumor) 
stemness 
 
ABCG2 (BCRP1) ATP-binding cassette, sub-family G (WHITE), member 2  
CD34 CD34 molecule  
CD44 CD44 molecule   
CXCR4 Chemokine (C-X-C motif) receptor 4  
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  
LIFR Leukemia inhibitory factor receptor  
NES* Nestin  
Notch pathway  
(and related) 
 
DLK1* Delta-like 1 homolog  
DLL1* Delta-like 1  
DLL3* Delta-like 3  
DLL4* Delta-like 4  
HES1* Hairy and enhancer of split1  
HEY2* Hairy/enhancer-of-split related with YRPW motif 2  
JAG1* Jagged1  
JAG2* Jagged 2  
NOTCH1* Notch gene homolog 1  
NOTCH2 Notch gene homolog 2  
NOTCH4* Notch gene homolog 4  
TGFβ/BMP 
pathway  
(and related) 
 
BMP2 Bone morphogenetic protein 2  
BMPR2 Bone morphogenetic protein receptor 2  
TGFB2 Transforming growth factor, beta 2  
TGFB1* Transforming growth factor, beta 1  
TGFBI Transcription factor, beta-induced  
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TGFBR2 Transforming growth factor, beta receptor II  
WNT/-catenin 
pathway  
(and related) 
 
DKK1* Dickkopf homolog 1  
DKK2* Dickkopf homolog 2  
DKK3 Dickkopf homolog 3  
DKK4 Dickkopf homolog 4  
FZD1* Frizzled 1 homolog  
FZD10 Frizzled 10 homolog  
TCF3* Transcription factor 3  
TCF7L1 Transcription factor 7-like 1  
TCF7L2 Transcription factor 7-like 2  
WNT5a* Wingless-related MMTV integration site 5A  
EMT  
CXCR4 Chemokine (C-X-C motif) receptor 4  
FN1 Fibronectin   
SNAI1* SNAIL homolog 1   
SNAI2 (SLUG)* SNAIL homolog 2  
VIM Vimentin  
ZEB1* Zinc finger E-box binding homeobox 1  
ZEB2 Zinc finger E-box binding homeobox 2  
Angiogenesis/ 
endothelial 
 
VCAM1 Vascular cell adhesion molecule 1  
VWF von Willebrand factor  
aSelection of genes as analyzed by microarray; genes are listed alphabetically per group 
bExpression level of the gene in the adenoma CD31¯/CD45¯ SP (pSP): ( ) when >1.5-fold 
upregulated in pSP versus pMP in all 5 of the adenoma samples; ( ) in 4 out of the 5 tumors; 
( ) in 3 out of the 5 tumors; ( ) in 2 out of the 5 tumors; ( ) when >1.5-fold downregulated 
in at least 3 of the 5 tumors. Indicated as ( ) when <1.5-fold difference versus MP. 
* means >1.5-fold upregulation but p>0.05. 
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